Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monofer versus red blood cell transfusion for severe postpartum iron deficiency anemia
2012-005783-10Phase 3Completed
- Sponsor
- Pharmacosmos
- Start
- May 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric derisomaltose in iron deficiency anemia (IDA) and postpartum anemia (2 arms), sponsored by Pharmacosmos. Primary endpoint: Aggregated change in physical fatigue score from baseline to week 12. Started May 2013; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)postpartum anemia
Beyond the preview
Go deeper on 2012-005783-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005783-10.